Friday, 17 Aug 2018

You are here

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297). Authors aimed at identifying association between CVRF and presence of either arthritis or skin disease. 

In this study of 300 patients with PSA, PSO and SpA, 29.7% reported Hypertension (HTN), 11.7% Type 2 Diabetes Melitus(T2DM) and 29% Dyslipidemia (DL). In comparison with general population entire study group comprised 100 patients with SpA without PSO (33.3%), 100 patients with PsA (33.3%) and PSO without articular disease (13%) exhibited higher prevalence of HTN and DL (p <0.005). Inside the study group though, where was no significant difference in prevalence of CVEF between all three studied diagnoses ( Fig below).

HTN was significantly associated with AINEs intake (OR 1.79; p<0.005) and disease duration (OR 1.02). No association with gender or age was found in this study.  neither PSA/SpA nor PSO were associated with development of T2DM or dyslipidemia. 

Study concluded that although prevalence of CVRF was higher in the study group comparing to general population, no significant difference was found in regards to skin vs articular disease. authors hint at association between NSAIDs use and HTN which would require further studies to specify.

image2.jpeg

 

image3.jpeg

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Back Pain in Psoriatic Arthritis

A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients. 

Minimal Disease Activity: The Goal in PsA

The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.